Argenx Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on July 23, 2026.
Q2 2026
EPS
$7.32
est $6.19
+18.2%
Revenue
$1.52B
est $1.43B
+5.7%
VYVGART's expanded label is working: argenx grew revenue 60% to $1.52B and beat EPS by 18% as its star neurology franchise locks in coverage for 55% of U.S. commercial lives across all adult myasthenia gravis serotypes, with Japan sales alone up 117% year-over-year.
Mentioned: ARGX